Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion type Assertion NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_head.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion description "[Complex EGFR mutations are not rare. Gefitinib has different efficacy according to the type of complex EGFR mutations. Patients with Del-19 and L858R mutations may benefit more from gefitinib than other types of complex mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_provenance.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion evidence source_evidence_literature NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_provenance.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion SIO_000772 20808254 NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_provenance.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion wasDerivedFrom gad-20150221 NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_provenance.
- NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_assertion wasGeneratedBy ECO_0000203 NP184887.RAQE5gD13GKCerZVQ8Qa36n5ZdPv3gZRCMoE1SAboLjsU130_provenance.